spacer
home > ebr > winter 2003 > drug discovery in the post-genomic era
PUBLICATIONS
European Biopharmaceutical Review

Drug Discovery in the Post-Genomic Era

2003 marked the completion of the human genome project and we now find ourselves in a post-genomic era, trying to understand and utilise a previously unimaginable amount of biological information. Scientists have the daunting task of finding new ways to use the human genome sequence for the benefit of humanity - to develop new drugs and to find better ways to combat disease.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Steve Lombardi, Vice President of Corporate Development at Affymetrix, Inc

Steve Lombardi is Vice President of Corporate Development at Affymetrix, Inc. He has made significant progress in moving early-stage, advanced technology out to customers. Prior to joining Affymetrix, Steve was Senior Vice President of Applications and Products for Applied Biosystems, managing strategic marketing and applications R&D. He earned his BA in Biology from Merrimack College.

spacer
Steve Lombardi
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

Convergence in the Pharmaceutical Market

PCI Pharma Services

Convergence is currently playing a large part in the growth of the pharmaceutical market. The need for convergence is due to many factors including the declining economy and high competition within the sector. There are many convergences within this sector to date; these include the convergence of food based products with medical and health products and the convergence of prescription drugs to over the counter (OTC) products. Although convergence is helping the pharmaceutical industry expand and develop, it also poses some challenges; these include the regulatory outlook and counterfeiting.
More info >>

 
Industry Events

Clinical Trial Supply Europe

11-12 March 2020, Madrid, Spain

The 21st annual edition promises to grow on the success of 2019’s excellent conference which saw delegates from Europe’s largest pharmaceutical companies and biotech innovators come together to discuss, debate and unpack the latest trends in clinical supply chain innovation. 2020 will offer delegates the opportunity to address the growing need for agility within the supply chain in response to increasingly complex trial demands. With a stream dedicated to supply operations and another to innovative uses of technology in the supply chain, delegates will get the chance to gain practical take-aways that they can apply to their own studies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement